Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Multicenter, Dose-escalation and Cohort Expansion Phase 1 Clinical Study of ES014 Administered in Patients Locally Advanced or Metastatic Solid Tumours

Next Previous
Trial Profile

An Open-label, Multicenter, Dose-escalation and Cohort Expansion Phase 1 Clinical Study of ES014 Administered in Patients Locally Advanced or Metastatic Solid Tumours

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ES 014 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Elpiscience Biopharmaceuticals

Most Recent Events

  • 23 Jun 2025 Status changed from recruiting to active, no longer recruiting.
  • 05 Aug 2024 Planned number of patients changed from 70 to 120.
  • 27 Feb 2023 According to a Elpiscience Biopharmaceuticals media release, Professor Lu Shun, Director of Oncology Department of Shanghai Chest Hospital is the principal investigator of this study.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top